Accelerate Diagnostics, Inc. (Nasdaq:AXDX) announced on December 8, 2015 that it has commenced an underwritten public offering of $80 million of shares of its common stock. All of the shares are being offered by Accelerate Diagnostics. In addition, Accelerate Diagnostics expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $12 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Accelerate Diagnostics anticipates using the net proceeds from the offering for general corporate purposes.
Based in Tucson, Arizona, Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistant organisms. The company’s investigational ID/AST platform utilizes proprietary molecular and phenotypic detection technologies which have the potential to significantly decrease the time to result while achieving high sensitivity and specificity.
To see the current stock charts, click here: http://www.nasdaq.com/symbol/axdx/stock-chart
To learn more about the offering, click here: http://globenewswire.com/news-release/2015/12/08/793918/10158166/en/Accelerate-Diagnostics-Announces-Proposed-Public-Offering-of-Common-Stock.html
Dec. 9, 2015 (GLOBE NEWSWIRE) — Accelerate Diagnostics, Inc. (Nasdaq:AXDX) today announced the pricing of an underwritten public offering of 5,588,236 shares of its common stock at a price to the public of $17.00 per share.